Registration Now Open!
Registration for the 2017 MD/PhD Student Conference is now open!
2017 Keynote Speakers
Emery N. Brown, M.D., Ph.D. - Neural signal processing algorithms.
Emery Brown is the Warren M. Zapol Professor of Anaesthesia at Harvard Medical School, an anesthesiologist at Massachusetts General Hospital, and the Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience at MIT, where he is an investigator in the Picower Center for Learning and Memory. The Brown lab is interested in using statistical methods to dissect neural network firing patterns and understand the mechanism of general anesthesia. Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Engineering, and the National Academy of Inventors. He received his B.A., M.A., M.D., and Ph.D. from Harvard University, trained in internal medicine Brigham and Women's Hospital, and completed his anesthesiology residency at Massachusetts General Hospital.
Donald Ingber, M.D., Ph.D. - Tissue Morphogenesis, Cell Engineering, and Complex Systems Biology.
Donald Ingber is the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences, and the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr. Ingber’s independent scientific program entails a multifaceted effort to develop breakthrough bioinspired technologies to advance healthcare and to improve sustainability in diverse areas including mechanobiology, tissue engineering, systems biology, nanobiotechnology and translational medicine. He has co-founded five companies. He is a member of the National Academy of Medicine, National Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University and completed post-doctoral training at Harvard Medical School.
Kim Orth, Ph.D. - Bacterial strategies for infection and survival.
Kim Orth is the Earl A. Forsyth Chair in Biomedical Science and Professor of Molecular Biology and Biochemistry at the University of Texas-Southwestern Medical Center. The Orth Lab is interested in studying virulence factors found in pathogenic bacteria to gain molecular insight into eukaryotic signaling systems and host-pathogen interactions. Dr. Orth is an investigator of the Howard Hughes Medical Institute, and the recipient of the American Society for Biochemistry and Molecular Biology Young Investigator Award, and the Norman Hackerman Award in Chemical Research. Dr. Orth received her B.A. from Texas A&M University, her M.S. from the University of California, Los Angeles, her Ph.D. from the University of Texas-Southwestern Medical Center, and completed her postdoctoral training at the University of Michigan.
Douglas Lowy, M.D. - Papillomaviruses in cancer biology and vaccine development.
Douglas Lowy is the Chief of the Laboratory of Cellular Oncology and the Acting Director of the National Cancer Institute (NCI) of the National Institutes of Health (NIH). Dr. Lowy’s lab is currently focused on basic and translational aspects of human papillomavirus infection, as well as cancer genetics and the biology of the Rho-GTPase family. A cancer researcher for more than 40 years, Dr. Lowy received the National Medal of Technology and Innovation from President Obama in 2014 for his research that has led to the development of the human papillomavirus (HPV) vaccine. Additionally, Dr. Lowy is a member of the National Academy of Sciences, and is a recipient of the Federal Employee of the Year Service to America Medal, and the Albert B. Sabin Gold Medal Award. Dr. Lowy received his B.A. from Amherst College, his M.D. from New York University School of Medicine, and trained in internal medicine at Stanford University, and dermatology at Yale University.
Kevan Shokat, Ph.D. - Chemical approaches to deciphering and controlling signal transduction pathways.
Kevan Shokat is a professor and the vice-chair of the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco, and a professor in the Department of Chemistry at the University of California, Berkeley. Dr. Shokat is a pioneer in the field of chemical genetics. His lab is interested in understanding the role of each kinase in the body with the goal of learning which kinases should be targeted to treat diseases such as cancer and immune dysfunction. Dr. Shokat is an investigator of the Howard Hughes Medical Institute and has received numerous awards including being a Pew, Searle, and Sloan Fellow. He has co-founded multiple companies including Intellikine (acquired by Takeda Pharmaceuticals) and Cellular Genomics Inc. (acquired by Gilead Biosciences). He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. He received his B.A. from Reed College, earned his Ph.D. from the University of California, Berkeley, and completed his post-doctoral training at Stanford University.
2017 Special Breakout Sessions
Interfacing with Industry - Dr. Peter S. Hammerman MD, Ph.D.
Peter S. Hammerman joined Novartis Institute for BioMedical Research in September of 2016 as Global Head of Oncology Translational Research. Dr. Hammerman is a Medical Oncologist and previously headed a translational research laboratory at the Dana-Farber Cancer Institute focusing on experimental therapeutics in lung and head and neck cancers. He practiced as an attending physician and clinical trialist in the Lowe Center for Thoracic Oncology at Dana-Farber and was an Assistant Professor of Medicine at Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. Dr. Hammerman is a graduate of Stanford University and received his MD and PhD degrees from the University of Pennsylvania School of Medicine completing his thesis research under Dr. Craig Thompson. He trained in Internal Medicine at the Massachusetts General Hospital and in Hematology-Oncology at Dana-Farber. He completed post-doctoral research training at Dana-Farber and the Broad Institute in the laboratory of Dr. Matthew Meyerson.